Skip to content

Recovery

Apraglutide

Also called FE 203799

InjectableEvidence AOnce a week
Half-life
30hours
Typical vial
5mg
Research amounts
2.5–5mg

per administration

Common schedule
Once a week
Tested in people

A human trial worked out how much to take and how often, so a dosing schedule is shown.

Work out your draw

These numbers are a starting point — change any of them.

3 mL cartridge · 300 units loaded150units dialled
Concentration
1.67mg/mL
Volume per draw
1.5mL
Units to dial
150
Doses per cartridge
2

This is 150 units, past the 60-unit dial. Splitting it across administrations, or using less water to raise the concentration, brings it back into range.

Dial range varies by pen; 1–60 units is the common configuration.

Vial label

Copy this into your label printer.

Published research contexts for Apraglutide describe 2.55 mg per administration. Descriptive only, not a recommendation.

Around 30 hours in reported work; supports weekly spacing.

Dosing schedule

How Apraglutide is commonly stepped up, for reference only.

These are commonly-discussed research protocols shared for educational reference. This is not medical advice and is not a substitute for guidance from a qualified professional.

PhaseAmountFrequencyRoute
Reported doseA long-acting GLP-2 analog dosed weekly in the STARS phase-3 program.2.5–5 mgOnce weeklySubQ

Modelled level — once a week

1× is the peak after a single dose.

Steady-state peak
0.99× single dose

Read off the modelled curve, not an even-interval formula

Time to steady state
6.3days

About five half-lives

Administrations
1/ week

Where these numbers come from

  • Apraglutide STARS phase-3 programWeekly subcutaneous apraglutide (FE 203799) at 2.5–5 mg assessed for intestinal absorption in short-bowel syndrome.

Next steps

Others in recovery